Department of Laboratory Medicine, Sichuan Academy of Medical Sciences and Sichuan Provincial People's Hospital, Chengdu, Sichuan, China.
J Evid Based Med. 2018 May;11(2):101-104. doi: 10.1111/jebm.12296. Epub 2018 May 14.
IL-22 plays an important role in cancer carcinogenesis. However, the association between IL-22 polymorphisms and cancer risk was inconclusive. The objective of the current study was to assess these associations by meta-analysis.
PubMed, EMbase, CNKI, VIP, and Wanfang databases were searched up to 31 January 2018. The results were screened according to the inclusion and exclusion criteria. The associations between polymorphisms and cancer risk were estimated by meta-analysis. All analyses were performed using the Revman5.3 software.
A total of four polymorphisms (rs2227485, rs1179251, rs1179246, and rs1182844) in seven studies were included. The results of meta-analysis indicated that the rs1179251 polymorphism [OR = 1.46, 95% CI (1.17, 1.82), P = 0.0008 for GG+GC vs. CC] was associated with increased risk of cancer, while the rs2227485, rs1179246, and rs1182844 polymorphisms were not associated with cancer risk.
The current meta-analysis suggests that IL-22 gene rs1179251 polymorphism may be a risk factor for cancer.
IL-22 在癌症发生中起着重要作用。然而，IL-22 多态性与癌症风险之间的关联尚无定论。本研究旨在通过荟萃分析来评估这些关联。
检索PubMed、EMbase、CNKI、VIP 和万方数据库，检索时间截至 2018 年 1 月 31 日。根据纳入和排除标准筛选结果。使用荟萃分析评估多态性与癌症风险之间的关联。所有分析均使用 Revman5.3 软件进行。
共有 7 项研究中的 4 个多态性（rs2227485、rs1179251、rs1179246 和 rs1182844）被纳入。荟萃分析结果表明，rs1179251 多态性[OR=1.46，95%CI（1.17，1.82），P=0.0008，GG+GC 与 CC 相比]与癌症风险增加相关，而 rs2227485、rs1179246 和 rs1182844 多态性与癌症风险无关。
本荟萃分析表明，IL-22 基因 rs1179251 多态性可能是癌症的一个危险因素。
